Name	**Jae-Sook Ahn**	
Current Position	**Professor in Chonnam National University Hwasun Hospital**	
Country	**South Korea**	
Major Field	Hematology	

Educational Background

Feb. '01: Graduated from Chonnam University Medical School

Received the M.D. and Bachelor of Medical Science

Feb. '04: Received the Master of Medical Science from Graduate School of Chonnam National University, Korea

Aug. '07: Received Ph.D. in Medicine from Graduate School of Chonnam National University, Korea

Professional Experience

Mar. '07-present time: Professor of Internal Medicine (Department of Hematology-Oncology)

in Chonnam National University Hwasun Hospital, Korea

Feb. '18-Jan. '20: Visiting Professor of Department of Molecular Genetics, University of Toronto, Canada

Mar. '06-Feb. '07: Fellowship in Department of Hematology-Oncology

in Chonnam National University Hwasun Hospital, Korea

Mar. '02-Feb. '06: Residency in Internal Medicine

at Chonnam National University Hospital

Mar. '01-Feb. '02: Internship at Chonnam National University Hospital

Other Experience and Professional Memberships

The Korean Medical Association

The Korean Association of Internal Medicine

The Korean Society of Hematology

The Korean Cancer Association

Main Scientific Publications

1. Ahn SY, Kim T, Kim M, Song GY, Jung SH, Yang DH, et al. Clinical Significance of bZIP in-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia. Cancer Res Treat. 2023; doi:10.4143/crt.2022.1407. **[Corresponding Author]**
2. YS Ji, JS Ahn, J Yun, GH Jang, SH Lim, SH Kim, CK Kim, JH Won, SK Park. Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea. Yonsei Med J, 2023 Feb;64(2):123-132. [**First Author]**
3. Song GY, Kim T, Ahn SY, Jung SH, Kim M, Yang DH, et al. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia. Bone Marrow Transplant. 2022;57:1810-9. **[Corresponding Author]**
4. Ahn JS, Kim T, Jung SH, Ahn SY, Song GY, Kim M, et al. Next-generation sequencing-based analysis to assess the pattern of relapse in patients with Philadelphia-positive acute lymphoblastic leukemia. EJHaem. 2022;3:1145-53. [**First Author]**
5. Ahn JS, Kim HJ. FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 2022;57:32-6. [**First Author]**
6. JS Ahn. Molecular Risk Stratification using Next-generation Sequencing in Acute Myeloid Leukemia. Korean J Med 2021;96(6):493-500. [**First Author]**
7. Jae-SookAhn[#1,2,3], TaeHyung Kim[#3,4], Sung-Hoon Jung[1], et al, Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. Bone Marrow Transplant. 2021 May;56(5):1159-1170. doi: 10.1038/s41409-020-01165-x. Epub 2020 Dec 5. [**First Author]**
8. M Kim[1], Hyun-Jin Bang[1], Ga-Young Song[1], et al. Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report Electrolyte Blood Press. 2021 Dec;19(2):46-50. **[Corresponding Author]**
9. Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. Ahn JS, Kim T, Kim YK, Cho YC, Cho S, Jung SH, Ahn SY, Jung SY, Yang DH, Lee JJ, Choi S, Lee JY, Shin MG, Yoshida K, Ogawa S, Kim IC, Zhang Z, Kim HJ, Kim DDH.Exp Hematol. 2019 Jul;75:26-30. doi: 10.1016/j.exphem.2019.06.001. Epub 2019 Jun 12. [**First Author]**
10. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Choi SH, Lee JY, Tyndel MS, Shin MG, Lee YJ, Sohn SK, Park SK, Zhang Z, Kim HJ, Kim DDH. Blood. 2018 Oct 11;132(15):1604-1613. doi: 10.1182/blood-2018-04-848028. Epub 2018 Aug 14. [**First Author]**